RxDoctor Payments Data

Zhigao Huang, MD

Neurology · Jacksonville, FLNPI 1861461964

Payments from drug & device makers

$612,635in general payments, 2019–2025

Across 1,699 payments — averaging $360.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$147K
  • Teva Pharmaceuticals USA, Inc.$145K
  • Neurocrine Biosciences, Inc.$125K
  • AbbVie$69K
  • Adamas Pharmaceuticals, Inc.$57K
  • Acorda Therapeutics, Inc$25K
  • plus $44K from 54 others

What the payments were for

  • Consulting fees$48,7348%
  • Speaking & faculty fees$503,96382%
  • Travel & lodging$28,3695%
  • Food & beverage$30,0765%
  • Education$1,4930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
MDD US Operations, LLC193$147,007
Teva Pharmaceuticals USA, Inc.269$144,558
Neurocrine Biosciences, Inc.159$125,309
AbbVie(2 entities)412$69,415
Adamas Pharmaceuticals, Inc.85$57,343
Acorda Therapeutics, Inc38$25,245
Acadia Pharmaceuticals Inc49$15,285
Kyowa Kirin, Inc.22$6,806
Sunovion Pharmaceuticals Inc.9$5,923
Amneal Pharmaceuticals LLC35$4,740
Amgen(2 entities)56$1,333
Vertex2$827
Novartis52$821
Eisai Inc.24$735
Jazz Pharmaceuticals Inc.25$578
Lundbeck LLC23$524
Lilly USA, LLC19$434
AstraZeneca(2 entities)18$413
Boston Scientific16$373
Biogen18$362
Argenx US, Inc.6$362
UCB, Inc.10$311
Pfizer14$299
SK Life Science, Inc.5$239
Otsuka America Pharmaceutical, Inc.6$228
Greenwich Biosciences, Inc.8$220
Sanofi11$202
Upsher-smith Laboratories LLC9$177
Medtronic3$155
EMD Serono, Inc.3$145
Insightec,inc2$135
Harmony Biosciences LLC4$130
Avion Pharmaceuticals5$126
TG Therapeutics, Inc.1$126
Axsome Therapeutics, Inc.5$122
GE HealthCare6$122
Supernus Pharmaceuticals, Inc.9$120
Neurelis, Inc.5$109
Alnylam Pharmaceuticals Inc.6$107
Biohaven Pharmaceutical Holding Company Ltd.4$96
CSL Behring3$88
Octapharma USA, Inc.3$71
Biohaven Pharmaceuticals, Inc.3$69
Averitas Pharma Inc.2$65
Abbott4$64
Impel Pharmaceuticals Inc.3$60
Merz Pharmaceuticals, LLC2$57
Arbor Pharmaceuticals, Inc.3$48
Johnson & Johnson3$46
E.r. Squibb & Sons, L.L.C.2$39
Scilex Pharmaceuticals Inc.2$38
Tanabe Pharma America, Inc.2$35
Microtransponder, Inc.1$34
Impel Pharmaceuticals LLC2$31
Assertio Therapeutics, Inc.2$29
Genentech USA, Inc.2$29
Revance Therapeutics, Inc.1$26
Flowonix Medical Incorporated1$26
Bausch Health US, LLC1$24
Idorsia Pharmaceuticals US Inc1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$612,635 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$635,393
Medicare patients
1,043
Services billed
53,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate103$898,170
GocovriAmantadine Hcl152$430,261
ApokynApomorphine Hcl13$321,475
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$249,337
NuplazidPimavanserin Tartrate38$224,056
BotoxOnabotulinumtoxina161$180,616
RytaryCarbidopa/Levodopa115$143,014
NeuproRotigotine26$59,122
Tetrabenazine23$52,569
Carbidopa-LevodopaCarbidopa/Levodopa1,272$48,088
QuliptaAtogepant25$28,952
XadagoSafinamide Mesylate16$28,012
Rasagiline Mesylate108$24,835
Glatiramer Acetate17$23,562
UbrelvyUbrogepant21$22,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$125,309$908,554117 claims
MDD US Operations, LLCGocovri$147,007$430,261152 claims
AbbVieBotox, Qulipta, Ubrelvy$69,415$231,645207 claims
Acadia Pharmaceuticals IncNuplazid$15,285$224,05638 claims
Amneal Pharmaceuticals LLCRytary$4,740$143,014115 claims
UCB, Inc.Neupro$311$59,12226 claims
Sunovion Pharmaceuticals Inc.Aptiom$5,923$18,94113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →